Literature DB >> 10935687

Patient-reported nonadherence to HAART is related to protease inhibitor levels.

R Murri1, A Ammassari, K Gallicano, A De Luca, A Cingolani, D Jacobson, A W Wu, A Antinori.   

Abstract

OBJECTIVE: To compare self-reported nonadherence with antiretroviral therapy (ART) with predose plasma levels of protease inhibitor (PI).
DESIGN: A cross-sectional study of consecutive patients from a university-based HIV clinic in Rome, Italy, was conducted. One hundred and forty HIV-infected patients were prescribed regimens containing ritonavir or indinavir. A patient questionnaire assessing knowledge of treatment regimen, adherence behavior, reasons for taking and missing therapy, factors influencing adherence, and health behaviors was administered. A predose PI plasma level was measured concurrently.
RESULTS: By patient report, 12% missed at least one dose "yesterday," and 24% missed doses in the last 3 days; 14% had a predose plasma concentration below the assay limit of quantitation (2 ritonavir and 18 indinavir samples). Confusion, poor psychological well-being, long office wait, running out of drugs between visits, having relatives to remind the patient to take medication, children, and alteration of sense of taste were related to unquantifiable predose levels of PI. In multivariable analysis, reported nonadherence (odds ratio [OR], 15.8; 95% confidence interval [CI], 4.0-63.3) and confusion (OR, 9.9; 95% CI, 1.4-69.6) were related to unquantifiable predose levels of PI.
CONCLUSION: Self-report of missing a dose of antiretroviral medication "yesterday" was related to an unmeasurable plasma PI level.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10935687     DOI: 10.1097/00126334-200006010-00006

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  28 in total

Review 1.  Measuring adherence to highly active antiretroviral therapy: implications for research and practice.

Authors:  Thomas Kerr; John Walsh; Elisa Lloyd-Smith; Evan Wood
Journal:  Curr HIV/AIDS Rep       Date:  2005-11       Impact factor: 5.071

2.  Assessing antiretroviral adherence via electronic drug monitoring and self-report: an examination of key methodological issues.

Authors:  Cynthia R Pearson; Jane M Simoni; Peter Hoff; Ann E Kurth; Diane P Martin
Journal:  AIDS Behav       Date:  2007-03

3.  A 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART.

Authors:  Carol E Golin; Joanne Earp; Hsiao-Chuan Tien; Paul Stewart; Carol Porter; Lynn Howie
Journal:  J Acquir Immune Defic Syndr       Date:  2006-05       Impact factor: 3.731

Review 4.  Practical and conceptual challenges in measuring antiretroviral adherence.

Authors:  Karina M Berg; Julia H Arnsten
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

5.  A Multi-step Usability Evaluation of a Self-Management App to Support Medication Adherence in Persons Living with HIV.

Authors:  Melissa Beauchemin; Melissa Gradilla; Dawon Baik; Hwayoung Cho; Rebecca Schnall
Journal:  Int J Med Inform       Date:  2018-12-03       Impact factor: 4.046

6.  Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure.

Authors:  M Fabbiani; L Bracciale; E Ragazzoni; R Santangelo; P Cattani; S Di Giambenedetto; G Fadda; P Navarra; R Cauda; A De Luca
Journal:  Infection       Date:  2011-08-25       Impact factor: 3.553

7.  The information-motivation-behavioral skills model of ART adherence in a Deep South HIV+ clinic sample.

Authors:  K Rivet Amico; William Barta; Deborah J Konkle-Parker; Jeffrey D Fisher; Deborah H Cornman; Paul A Shuper; William A Fisher
Journal:  AIDS Behav       Date:  2007-09-18

Review 8.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

9.  Reasons for ART non-adherence in the Deep South: adherence needs of a sample of HIV-positive patients in Mississippi.

Authors:  K Rivet Amico; D J Konkle-Parker; D H Cornman; W D Barta; R Ferrer; W E Norton; C Trayling; P Shuper; J D Fisher; W A Fisher
Journal:  AIDS Care       Date:  2007-11

10.  Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda.

Authors:  Andrew M Abaasa; Jim Todd; Kenneth Ekoru; Joan N Kalyango; Jonathan Levin; Emmanuel Odeke; Charles A S Karamagi
Journal:  BMC Health Serv Res       Date:  2008-11-20       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.